Welcome to our dedicated page for COGNITION THERAPEUTICS SEC filings (Ticker: CGTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cognition Therapeutics, Inc. filings document a clinical-stage biopharmaceutical issuer developing zervimesine for neurodegenerative diseases. Its Form 8-K reports cover financial results, Regulation FD presentations, clinical-development announcements, FDA meeting disclosures, and material agreements, including an at-the-market common-stock sales arrangement.
Proxy materials disclose annual meeting and stockholder voting matters, while registration and current-report disclosures identify the company’s Delaware corporate status, emerging growth company reporting status, and Nasdaq-listed common stock. The filings also provide formal records of capital-structure activity, governance processes, and risk areas associated with clinical research, regulatory review, grant funding, and the financing needs of a development-stage biotechnology company.
Cognition Therapeutics, Inc. furnished an investor presentation under Regulation FD, outlining its strategy as a clinical-stage CNS drug developer focused on zervimesine (CT1812). The company highlights Dementia with Lewy bodies (DLB) psychosis as its lead indication, with a Phase 3 registrational trial in development following the SHIMMER Phase 2 study.
As of March 31, 2026, Cognition reports approximately $31 million in cash, equivalents and restricted cash, $25 million in obligated NIA grant funds, and a cash runway into Q2 2027 based on its current operating plan. The presentation notes more than $170 million in cumulative NIH/NIA grant support and a workforce of about 14 employees.
The deck describes SHIMMER Phase 2 results in DLB, including slowing of neuropsychiatric decline on the NPI-12 measure versus placebo, and plans for a 9‑month registrational study in DLB psychosis overseen by the FDA’s Division of Psychiatry. It also details Alzheimer’s programs, including the completed SHINE Phase 2 trial and the ongoing 545‑patient START trial in MCI through mild Alzheimer’s disease funded by an $81 million NIA grant.
Cognition Therapeutics reported that it has completed a planned meeting with the U.S. Food and Drug Administration to discuss zervimesine (CT1812) for dementia with Lewy bodies patients with psychosis. The discussion reviewed Phase 2 SHIMMER results and potential design and endpoints for a registrational trial.
The company said the interaction was productive and believes there is a path forward to develop zervimesine for DLB psychosis, with formal FDA meeting minutes expected in June. Zervimesine is an investigational once-daily oral therapy that has shown promise in Phase 2 studies in DLB and mild-to-moderate Alzheimer’s disease.
Cognition noted it has received nearly $200 million in grants from the National Institutes of Health and related foundations to support its neurodegenerative disease research and clinical programs.
Cognition Therapeutics’ Q1 2026 report shows a smaller loss while it continues advancing its neurology pipeline. Net loss narrowed to $4,570 thousand, or $0.05 per share, compared with $8,480 thousand, or $0.14 per share, a year earlier. Operating expenses fell as research and development dropped to $6,120 thousand from $10,786 thousand, reflecting lower clinical program and personnel costs.
The company generated $3,979 thousand of grant income, mainly from U.S. National Institute on Aging awards funding its Alzheimer’s and dementia with Lewy bodies studies. Cash, cash equivalents and restricted cash totaled $31.2 million, and management believes this, together with existing NIA grant support, can fund operations through the second quarter of 2027. Lead candidate zervimesine (CT1812) remains in multiple Phase 2 programs for Alzheimer’s disease and DLB, with large NIA grants and a 2025 shelf registration and at-the-market program providing additional financing flexibility.
Cognition Therapeutics reported first-quarter 2026 results and a business update focused on its lead candidate zervimesine. Cash, cash equivalents and restricted cash were about $31.2 million as of March 31, 2026, with $25.6 million of obligated grant funds remaining, and the company estimates its cash will fund operations through the second quarter of 2027.
Research and development expenses fell to $6.1 million from $10.8 million a year earlier, while general and administrative expenses declined to $2.7 million from $3.0 million. Net loss narrowed to $4.6 million, or $(0.05) per share, compared with $8.5 million, or $(0.14) per share, on higher grant and other income.
The company highlighted a scheduled May 20, 2026 meeting with the FDA’s Division of Psychiatry to discuss a potential registrational study of zervimesine in dementia with Lewy body psychosis and reiterated that topline results from the 545-participant Phase 2 START Alzheimer’s study are anticipated in 2027.
Cognition Therapeutics Inc. Chief Financial Officer John Brendan Doyle reported a routine tax-related share disposition. On the vesting of restricted stock units, the company withheld 8,567 shares of common stock at $1.28 per share to cover tax withholding obligations. After this non-market transaction, Doyle directly holds 618,942 shares of Cognition Therapeutics common stock, indicating he retains a substantial equity stake following the RSU vesting.
Cognition Therapeutics, Inc. is asking stockholders to vote at its 2026 Annual Meeting, held virtually on June 17, 2026 at 9:00 a.m. Eastern. Holders of common stock at the close of business on April 20, 2026 (89,353,773 shares outstanding) may vote.
Stockholders will elect two Class II directors, Aaron Fletcher, Ph.D. and Lisa Ricciardi, to terms expiring in 2029, and ratify Ernst & Young LLP as independent registered public accounting firm for 2026. The six‑member board includes five independent directors and an independent chair.
The proxy also outlines corporate governance practices, committee structures, director pay, and 2025 executive compensation. In 2025, CEO Lisa Ricciardi received total compensation of about $1.46 million, including salary, RSUs and a performance bonus. The filing highlights recent clinical progress in dementia with Lewy bodies and Alzheimer’s disease.
Cognition Therapeutics Chief Financial Officer John Brendan Doyle bought 10,000 shares of common stock in an open-market purchase at $1.13 per share. The transaction involved directly held shares. Following this purchase, Doyle directly owns a total of 627,509 shares of Cognition Therapeutics common stock.
Cognition Therapeutics Inc CEO and President Lisa Ricciardi reported an open-market purchase of 9,175 shares of common stock at $1.10 per share on April 16, 2026. After this transaction, she directly holds 1,715,851 shares and indirectly holds 38,851 shares through her spouse.
Cognition Therapeutics Inc. Chief Medical Officer Anthony Caggiano reported an open-market purchase of 10,000 shares of the company’s Common Stock on April 16, 2026 at a price of $1.11 per share. Following this transaction, his direct holdings increased to 874,906 shares of Common Stock.